{'fraction_non_alphanumeric': 0.01694915254237288, 'fraction_numerical': 0.009322033898305085, 'mean_word_length': 4.9646464646464645, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
CCR7 is differentially expressed in the lymph nodes of patients with metastatic breast cancer.

Metastasis to the brain is a clinical problem in patients with breast cancer (1-3). The lymph nodes reside between the breast and the brain. We mined published microarray data (4, 5) to compare primary and metastatic tumor transcriptomes for the discovery of genes associated with metastasis to the lymph nodes in humans with metastatic breast cancer. We found that the C-C chemokine receptor type 7, CCR7, was among the genes whose expression was most different in the lymph node metastases of patients with metastatic breast cancer as compared to primary tumors of the breast. CCR7 mRNA was present at increased quantities in lymph node metastases as compared to primary tumors of the breast. Importantly, expression of CCR7 in primary tumors of the breast was significantly correlated with patient recurrence-free survival. Modulation of CCR7 expression may be relevant to the biology by which tumor cells metastasize from the breast to the brain in humans with metastatic breast cancer. CCR7 may function to support tissue infiltration in brain metastatic breast cancer in humans.